Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8251 to 8265 of 8905 results

  1. Partial-onset seizures in epilepsy: perampanel as adjunctive treatment (ESNM7)

    This evidence summary has been updated and replaced by NICE guideline NG217.

    Withdrawn advice

  2. Visual impairment due to myopic choroidal neovascularisation: aflibercept (ESNM76)

    This evidence summary has been replaced by NICE technology appraisal guidance 486.  

    Withdrawn advice

  3. Moderate to severe acute post-operative pain: fentanyl transdermal system (ESNM77)

    This evidence summary was withdrawn in September 2017 as the medicine is no longer available.

    Withdrawn advice

  4. Moderate to severe acute post­-operative pain: sufentanil sublingual tablet system (ESNM71)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Withdrawn advice

  5. Chronic obstructive pulmonary disease: aclidinium bromide (ESNM8)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  6. Significant haemorrhage following trauma: tranexamic acid (ESUOM1)

    This evidence summary has been updated and replaced by NICE guideline NG39.

    Withdrawn advice

  7. Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil) (ESNM78)

    This advice has been updated and replaced by NICE guideline NG221.

    Withdrawn advice

  8. Induction of labour in late intrauterine fetal death: vaginal misoprostol (after oral mifepristone) (ESUOM11)

    This evidence summary has been updated and replaced by NICE guideline NG207.

    Withdrawn advice

  9. Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  10. Hypersalivation: oral glycopyrronium bromide (ESUOM15)

    This evidence summary has been withdrawn because licensed products are now available and the off-label indication has been replaced by NICE guideline NG71.

    Withdrawn advice

  11. Nocturia and nocturnal polyuria in men with lower urinary tract symptoms: oral desmopressin (ESUOM10)

    This evidence summary has been withdrawn because a product containing oral desmopressin with a marketing authorisation for treating nocturia and nocturnal polyuria in men with lower urinary tract symptom is now available in the UK.

    Withdrawn advice

  12. Generalised anxiety disorder: quetiapine (ESUOM12)

    This evidence summary has been updated and replaced by NICE guideline CG113 and subsequent surveillance reviews.

    Withdrawn advice

  13. Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin (ESUOM2)

    This evidence summary has been withdrawn because licensed products are now available.

    Withdrawn advice

  14. Critical limb ischaemia in peripheral vascular disease: intravenous iloprost (ESUOM24)

    April 2019: This evidence summary has been withdrawn because a product containing intravenous iloprost with a marketing authorisation for treating critical limb ischaemia in peripheral vascular disease is now available in the UK.

    Withdrawn advice

  15. Multidrug resistant urinary tract infections: fosfomycin trometamol (ESUOM17)

    This evidence summary has been withdrawn because a product containing fosfomycin trometamol with a marketing authorisation for treating multidrug resistant urinary tract infections is now available in the UK.

    Withdrawn advice